Verdiva Bio

Transforming lives by accelerating innovation in cardiometabolic health

London, United Kingdom · Founded 2024 · $411.0M raised

Headquarters
London
Employees
11–50
Founded
2024
Business Model
B2B
Total Funding
$411.0M
Last Round
$411.0M Series AJan 2025
Rounds
1

About

Verdiva Bio is a clinical-stage biopharmaceutical company developing next-generation oral and injectable therapies for obesity and cardiometabolic disorders. Its lead asset VRB-101 is an oral, once-weekly GLP-1 peptide analog advancing through Phase 2 clinical trials, with additional pipeline programs including amylin agonists and combination therapies. The company launched in January 2025 with $411M in Series A financing and applies emerging gut-brain biology science to deliver more patient-friendly treatment options.

Summary

Verdiva Bio is a Life Sciences company based in London, United Kingdom, founded in 2024. It has raised $411.0M in total across 1 round, most recently a $411.0M Series A round in Jan 2025. Investors include Forbion Capital Partners, General Atlantic and RA Capital Management.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AJan 2025
$411.0M

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Verdiva Bio on Indexed.vc
<a href="https://indexed.vc/companies/verdiva-bio"><img src="https://indexed.vc/api/badge/company/verdiva-bio" alt="Verdiva Bio on Indexed.vc" width="260" height="76" /></a>